Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B

Executive Summary

Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B
Advertisement

Related Content

Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost
Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost
Biogen/Elan Tysabri Combination Use Higher Than Expected Since Launch
Biogen/Elan Tysabri Combination Use Higher Than Expected Since Launch
OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing
Biogen Idec Highlights Manufacturing Capacity To Attract Partnerships
Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy
Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy
Oral Cancer Drugs, MS Self-Injectables Covered In Medicare Pilot Program
CMS Medicare Self-Injectable Guidelines Maintain Split Within Drug Classes

Topics

Advertisement
UsernamePublicRestriction

Register

PS045050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel